| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/25/2006 | EP1619193A1 Spiropiperidine compound and medicinal use thereof |
| 01/25/2006 | EP1618892A1 Instrument for inducing cytokine and method of inducing cytokine |
| 01/25/2006 | EP1618883A1 Agent for preventing and ameliorating constipation |
| 01/25/2006 | EP1618878A1 Body-temperature lowering depressant |
| 01/25/2006 | EP1618874A2 Prevention of hiv-1 infection by inhibition of rho-mediated reorganisation and/or content alteration of cell membrane raft domains |
| 01/25/2006 | EP1618090A1 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
| 01/25/2006 | EP1617872A2 Methods and compositions for enhancing immune response |
| 01/25/2006 | EP1617871A2 Delivery of immune response modifier compounds using metal-containing particulate support materials |
| 01/25/2006 | EP1617849A1 Composition and uses of galectin antagonists |
| 01/25/2006 | EP1617846A1 The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome |
| 01/25/2006 | EP1617845A2 Compositions and methods for induction of opioid receptors |
| 01/25/2006 | EP1617844A1 Treatment of neurological conditions |
| 01/25/2006 | EP1617831A1 Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse |
| 01/25/2006 | EP1617828A2 Nano-sized vehicles transporting a therapeutic agent and at least one drug resistance modulator for the treatment of multi drug resistance |
| 01/25/2006 | EP1617827A1 Pharmaceutical composition in the form of a hydrogel for transdermal administration of active substances |
| 01/25/2006 | EP1617810A2 Methods for preparation and use of 1alpha,24(s)-dihydroxyvitamin d2 |
| 01/25/2006 | EP1617805A2 Methods of preventing or treating respiratory conditions |
| 01/25/2006 | EP1617734A1 Multi-vitamin and mineral supplement for pregnant women |
| 01/25/2006 | EP1617723A2 Bacteriophage for lysis of methylobacterium and compositions and uses thereof |
| 01/25/2006 | EP1461071A4 Muscle transcription factors |
| 01/25/2006 | EP1450787A4 Formulations and methods for treatment or amelioration of inflammatory conditions |
| 01/25/2006 | EP1267901B1 Compositions suitable for the treatment of damage caused by ischemia/reperfusion or oxidative stress |
| 01/25/2006 | EP1235825B1 Novel benzoimidazole derivatives useful as antiproliferative agents |
| 01/25/2006 | EP1144000B1 New dialysis method |
| 01/25/2006 | EP0914158B2 Pharmaceutical combination containing a compound having angiotensin ii antagonistic activity and a compound which increases the insulin-sensitivity |
| 01/25/2006 | EP0759781B1 Compositions for treating and preventing atherosclerosis |
| 01/25/2006 | CN1726048A Gastric acid secretion inhibiting composition |
| 01/25/2006 | CN1726039A Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
| 01/25/2006 | CN1726035A Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines |
| 01/25/2006 | CN1726028A Solid drug for oral use |
| 01/25/2006 | CN1726023A Pregabalin and derivatives thereof for the treatment of fibromyalgia and other related disorders |
| 01/25/2006 | CN1726022A Pregabalin derivatives for the treatment of fibromyalgia and other disorders and its derivitive |
| 01/25/2006 | CN1726021A Alpha2delta ligands for the treatment of sexual dysfunction |
| 01/25/2006 | CN1726018A Methods and compositions for the treatment of herpes virus infections using cyclooxygenase-2 selective inhibitors or cyclooxygenase-2 inhibitors in combination with antiviral agents |
| 01/25/2006 | CN1726016A Prevention and treatment of alzheimer's disease |
| 01/25/2006 | CN1726015A Alpha2delta ligands for different pharmaceutical uses |
| 01/25/2006 | CN1726010A Process for preparing combination pharmaceutical formulations using supercritical fluids |
| 01/25/2006 | CN1724570A Anthrax toxin acceptor ATR-Fc fusion protein |
| 01/25/2006 | CN1724071A Novel use of cell wall skeleton of red nocar-ray-fungus for treating liver diseases |
| 01/25/2006 | CN1724066A Controlled release composition and method of producing the same |
| 01/25/2006 | CN1238367C Isolated nucleic acid molecules which encode T cell inducible factors (TIF), proteins encoded, and uses thereof |
| 01/25/2006 | CN1238055C Medicine for curing metabolic syndrome |
| 01/25/2006 | CN1237971C Compound hypotension preparation containing angiotonin converzyme inhibitor, calcium ion antagonist and Estazolam |
| 01/25/2006 | CN1237970C Inhalant containing tiotropium salt solution |
| 01/25/2006 | CN1237968C Methods for inhibiting proliferation and inducing apoptosis of cancer cells |
| 01/25/2006 | CN1237959C Process for preparing pharmaceutical compositions for use with soft capsule |
| 01/24/2006 | US6989435 Compounds and methods to inhibit or augment an inflammatory response |
| 01/24/2006 | US6989402 Thyroid receptor ligands and method II |
| 01/24/2006 | US6989396 Anticancer agents; modulating glycoprotein |
| 01/24/2006 | US6989385 Pyrazole compounds useful as protein kinase inhibitors |
| 01/24/2006 | US6989383 Method of treating cancer |
| 01/24/2006 | US6989372 medicaments intended to increase the intracellular and/or extracellular level of glutathione (GSH); for example, N-(N-Acetyl-L-cysteinyl)-S-acetylcysteamine; hiv treatment |
| 01/24/2006 | US6989366 Exendins, exendin agonists, and methods for their use |
| 01/24/2006 | US6989364 treatment extends to all stages of progression of cardiac hypertrophy, with or without structural damage of the heart muscle, regardless of the underlying cardiac disorder |
| 01/24/2006 | US6989278 administering alcohol and an agent such as concanavalin A as a model for identification of therapeutic substances; Chinese herb CH-100 proved useful in treatment of alcohol-induced hepatitis |
| 01/24/2006 | US6989262 Plasmin variants and uses thereof |
| 01/24/2006 | US6989260 Gene expression inhibition; for treatment of inflammatory, neurological, cardiovascular, and neoplastic tisssue growth disorders |
| 01/24/2006 | US6989255 for protection against staphylococcus infection; fusion proteins |
| 01/24/2006 | US6989153 Radiation sensitive liposomes |
| 01/24/2006 | US6989146 Stress proteins and peptides and methods of use thereof |
| 01/24/2006 | US6988619 Medicinal product package for eradication therapy |
| 01/24/2006 | CA2339353C Fast dissolving orally consumable films |
| 01/24/2006 | CA2292984C Ccr5 modulators |
| 01/19/2006 | WO2006007358A1 Hypoestoxides, derivatives ans agonists thereof for use as stent-coating agents |
| 01/19/2006 | WO2006006933A2 Antiproliferative compositions comprising aryl substituted xylopyranoside derivatives |
| 01/19/2006 | WO2006006741A1 Fused benzamide compound and vanilloid receptor 1 (vr1) activity inhibitor |
| 01/19/2006 | WO2006006722A1 Method of controlling cell functions |
| 01/19/2006 | WO2006005415A2 Use of l-carnitine and glucose for the treatment of cardiovascular diseases |
| 01/19/2006 | WO2005107807A3 Cerebral intraventricular transplantation as method of treating amyotrophic lateral sclerosis |
| 01/19/2006 | WO2005099705A3 Preparation of imidazole derivatives and methods of use |
| 01/19/2006 | WO2005094218A3 Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| 01/19/2006 | WO2005054436A3 Compositions and methods for preservation of vascular grafts |
| 01/19/2006 | WO2005037317A3 Mast cell-derived renin |
| 01/19/2006 | US20060015961 Methods and compositions for producing germ cells from peripheral blood derived germline stem cells |
| 01/19/2006 | US20060014931 Novel promoter |
| 01/19/2006 | US20060014839 Combination of angiotensin II receptor blocker and beta-blocker for secondary prevention of myocardial infarction |
| 01/19/2006 | US20060014804 Cyanoguanidine prodrugs |
| 01/19/2006 | US20060014788 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
| 01/19/2006 | US20060014780 Nicotinamide derivatives useful as PDE4 inhibitors |
| 01/19/2006 | US20060014754 Methods and compositions for treating diseases and conditions of the eye |
| 01/19/2006 | US20060014716 Methods and compositions for protecting and treating muscarinic receptors by administering a pyrophosphate analog to a subject exposed to bacterial, fungal, viral, prion or algal infection |
| 01/19/2006 | US20060014678 adminsteration of Peptide YY and glucagons-like peptide-1( GLP-1) or agonists to a overweight subject, or having obesity related disorders, results in decreased food intake, caloric intake, appetite, and an alteration in energy metabolism |
| 01/19/2006 | US20060014243 Human G-protein chemokine receptor HSATU68 |
| 01/19/2006 | US20060014242 Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) |
| 01/19/2006 | US20060014222 Antibodies |
| 01/19/2006 | US20060014157 Sensitivity test to predict efficacy of anti-cancer therapies |
| 01/19/2006 | US20060013895 Use of a composition and a cleaning tablet containing said composition for disinfecting purposes |
| 01/19/2006 | US20060013869 Electrospun amorphous pharmaceutical compositions |
| 01/19/2006 | US20060013817 identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in an aberrant manner. |
| 01/19/2006 | US20060013812 Mixture comprising blood coagulation factor and serpin for use in prevention and treatment of blood disorders |
| 01/19/2006 | US20060013804 Modulation of stem cell differentiation by modulation of caspase-3 activity |
| 01/19/2006 | US20060013777 Novel treatment for cough |
| 01/19/2006 | US20060013775 Use of ppar activators for the treatment of pulmonary fibrosis |
| 01/19/2006 | DE102004032049A1 Gegen Missbrauch gesicherte, orale Darreichungsform Abuse-proofed oral dosage form |
| 01/19/2006 | CA2573611A1 Agent for promoting the recovery from dysfunction after the onset of central neurological disease |
| 01/19/2006 | CA2569888A1 Use of l-carnitine for the treatment of cardiovascular diseases |
| 01/18/2006 | EP1617219A1 Element having bioactive substance fixed thereto |
| 01/18/2006 | EP1617216A1 Novel method of screening |
| 01/18/2006 | EP1616958A2 Notch-ligands for use in immunotherapy |
| 01/18/2006 | EP1616954A2 Methods and reagents for vaccination which generate a CD8 T cell immune response |